Menora Mivtachim Holdings LTD Increased Its Stake in Mylan Nv (MYL) by $198.67 Million as Shares Declined

June 29, 2018 - By Nicole Mills

Mylan N.V. (NASDAQ:MYL) Corporate LogoBig Money Sentiment decreased to 1 in 2018 Q1. It has change of 2.00, from 2017Q4’s 3. The ratio dropped due to MYL positioning: 1 sold and 2 reduced. 3 funds amassed holdings and 0 increased holdings. Investors holded 292,846 in 2017Q4 but now own 190,596 shares or 34.92% less. Vantage Inv Advisors Ltd Liability Company holds 337 shs. Gulf Bank (Uk) Ltd invested in 139,000 shs or 0.07% of the stock. Van Hulzen Asset Management holds 0.39% of its capital in Mylan N.V. (NASDAQ:MYL) for 30,685 shs. Gemmer Asset Mgmt Ltd Llc has 0% invested in Mylan N.V. (NASDAQ:MYL) for 12 shs. Eqis Capital Incorporated accumulated 6,506 shs.

Based on the latest 2018Q1 regulatory filing with the SEC, Menora Mivtachim Holdings Ltd rose its stake in Mylan Nv (MYL) by 219.08%. 4.85M shares were bought by Menora Mivtachim Holdings Ltd as the company’s stock declined 5.74% with the market. The institutional investor is holding 7.06 million shares, compared to the 2.21 million from the previous quarter. And the reported value of the major pharmaceuticals company is $290.56 million for the 2018Q1. Mylan Nv has $18.91 billion market cap. Ticker’s shares touched $36.69 during the last trading session after 0.99% change.Currently Mylan N.V. is downtrending after 1.13% change in last June 29, 2017. MYL has 762,952 shares volume. MYL underperformed by 13.70% the S&P500.

The Menora Mivtachim Holdings Ltd’s stake in Nvidia Corp (NASDAQ:NVDA) was decreased by 70,375 shares to 89,491 shares valued at $20.73M in 2018Q1, according to the filing. It operates about $3.16B US Long portfolio. Menora Mivtachim Holdings Ltd has cut its stake in At & T Inc (NYSE:T) and also reduced its holding in Applied Matls Inc (NASDAQ:AMAT) by 125,000 shares in the quarter, for a total of 404,410 shares.

Another two news for Mylan N.V. (NASDAQ:MYL) were recently published by: Seekingalpha.com on June 04, 2018 with title “Mylan: A Margin Of Safety Case Study”. The other Streetinsider.com‘s article was titled “Mylan (MYL) Announces Launch of Generic Angiomax Injection” and published on June 18, 2018.

Mylan N.V. (NASDAQ:MYL) Ratings Coverage

Total analysts of 15 have positions in Mylan (NASDAQ:MYL) as follows: 11 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 73%. Since January 3, 2018 according to StockzIntelligence Inc Mylan has 20 analyst reports. On Thursday, May 31 the firm has “Market Perform” rating by Wells Fargo given. On Tuesday, June 5 the company was maintained by Guggenheim. On Thursday, April 12 the company was upgraded by Leerink Swann. On Thursday, March 15 Mizuho maintained Mylan N.V. (NASDAQ:MYL) rating. Mizuho has “Buy” rating and $51.0 target. On Tuesday, May 29 Bank of America maintained Mylan N.V. (NASDAQ:MYL) rating. Bank of America has “Neutral” rating and $42 target. On Thursday, March 1 the firm has “Hold” rating by Cantor Fitzgerald given. On Thursday, April 12 the firm earned “Buy” rating by Mizuho. On Tuesday, April 3 RBC Capital Markets maintained the shares of MYL in report with “Hold” rating. On Tuesday, March 6 the rating was upgraded by Morgan Stanley to “Overweight”. The company rating was upgraded by Goldman Sachs on Thursday, January 11.

Mylan N.V. (NASDAQ:MYL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.